Sensitive and Rapid Method for the Simultaneous Quantification of the HIV-Protease Inhibitors Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Plasma by Reversed-Phase Liquid Chromatography
- 1 February 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 23 (1), 56-60
- https://doi.org/10.1097/00007691-200102000-00011
Abstract
A rapid, sensitive, and specific liquid chromatography method for the simultaneous determination of four protease inhibitors (indinavir, nelfinavir, ritonavir, and saquinavir) in human plasma is described. After a liquid-liquid extraction with terbutyl methyl ether and a sequential washing of the reconstituted sample with hexane, protease inhibitors are separated on a phenyl column using a simple binary mobile phase of ammonium acetate buffer:acetonitrile (48:52) (pH = 7.5) with an ultraviolet detection at 260 nm. The standard curves are linear in the range 0.025–1 μg/mL for saquinavir, 0.1–4 μg/mL for indinavir and nelfinavir, and 0.25–10 μg/mL for ritonavir, with an average recovery ranging from 79% to 99%, and with both low interday and intraday coefficients of variation (Keywords
This publication has 16 references indexed in Scilit:
- Determination of Indinavir, A HIV-1 Protease Inhibitor, in Human Plasma Using Ion-pair Reversed-phase High-Performance Liquid ChromatographyTherapeutic Drug Monitoring, 1999
- Indinavir Concentrations and Antiviral EffectPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
- Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV‐1 infected individualsBritish Journal of Clinical Pharmacology, 1999
- Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1999
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999
- Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow‐up in Patients Infected with Human Immunodeficiency VirusThe Journal of Clinical Pharmacology, 1998
- Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1997
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)AIDS, 1996
- Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switchingJournal of Chromatography A, 1995